Literature DB >> 25066867

Frequent coexistence of RAS mutations in RUNX1-mutated acute myeloid leukemia in Arab Asian children.

Lika'a Fasih Y Al-Kzayer1, Kazuo Sakashita, Mazin Faisal Al-Jadiry, Salma Abbas Al-Hadad, Le T N Uyen, Tingting Liu, Kazuyuki Matsuda, Jaafar M H Abdulkadhim, Tariq Abadi Al-Shujairi, Zead Ismael I K Matti, Janan Ghalib Hasan, Hussam M Salih Al-Abdullah, Toshi Inoshita, Minoru Kamata, Maher A Sughayer, Faris F Madanat, Kenichi Koike.   

Abstract

BACKGROUND: RUNX1 mutation plays an important role in adult leukemic transformation. However, its contribution to the development of childhood leukemia remains unclear. In the present study, we analyzed point mutations of RUNX1 gene in children and adolescents with acute myeloid leukemia (AML) from Iraq and Jordan. PROCEDURE: Bone marrow and/or peripheral blood samples were collected from 178 patients of Arab Asian ethnicity (aged ≤17 years) newly diagnosed with AML: 145 samples from Iraq and 33 samples from Jordan. Direct DNA sequencing was performed on six genes including RUNX1 gene (exons 3-8).
RESULTS: RUNX1 point mutations were identified in 10 (5.6%) of 178 patients. One patient possessed biallelic mutations of RUNX1 gene. C-terminal area was the predominant site of RUNX1 mutations (eight in C-terminal and two in N-terminal). Patients with RUNX1 mutations were significantly older than those with wild-type of the gene. Additionally, AML M0 subtype was more frequently found in patients with RUNX1 mutations. Both RUNX1 mutations and RAS mutations were identified in 4 of 10 children. Three patients with RUNX1 mutation had FLT3-ITD. On the other hand, 36 (21.4%) and 25 (14.9%) of 168 patients with wild-type of the gene had a RAS mutation and FLT3-ITD, respectively. Eight of 10 patients with RUNX1 mutations died of hematological relapse.
CONCLUSION: The incidence of RUNX1 mutations in Arab Asian children and adolescents with AML was 5.6%. Further studies are required to clarify whether RAS mutations contribute to the development of pediatric AML associated with RUNX1 mutations.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  AML; C-terminal/N-terminal; FTA; MDS; RAS; RUNX1/AML1

Mesh:

Substances:

Year:  2014        PMID: 25066867     DOI: 10.1002/pbc.25151

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

Review 1.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

Review 2.  Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.

Authors:  Habsah Aziz; Chow Y Ping; Hamidah Alias; Nurul-Syakima Ab Mutalib; Rahman Jamal
Journal:  Front Pharmacol       Date:  2017-12-07       Impact factor: 5.810

3.  A Syrian Refugee in Iraq Diagnosed as a Case of IL12RB1 Deficiency in Japan Using Dried Blood Spots.

Authors:  Lika'a Fasih Y Al-Kzayer; Ahmed K Yassin; Khalid Hama Salih; Tomonari Shigemura; Kenji Sano; Ruwaid Behnam Y Al-Simaani; Miyuki Tanaka; Yozo Nakazawa; Yusuke Okuno
Journal:  Front Immunol       Date:  2019-01-25       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.